Melanoma and EGFR lung cancer HLA-I proteogenomics
downstream-application
Melanoma and EGFR lung cancer HLA-I proteogenomics: downstream-application. Proteogenomic HLA class I immunopeptidomics in melanoma and EGFR-mutant lung adenocarcinoma, using de novo search to find variant, PTM and lncRNA-encoded peptides.
Proteogenomic HLA class I immunopeptidomics in melanoma and EGFR-mutant lung adenocarcinoma, using de novo search to find variant, PTM and lncRNA-encoded peptides.
| Kind | downstream-application |
| Deep learning | no |
| Acquisition | DDA |
| Application area | Immunopeptidomics / neoantigen |
Data
What the papers describing this method trained it on and reported its results on, as each paper states it. A version is named only where the paper names one.
Deposited
- Proteogenomic analysis unveils the HLA Class I presented immunopeptidome in melanoma and EGFR mutant lung adenocarcinoma (as deposited)
- Proteogenomic analysis unveils the expression of cancer associated and specific antigen-derived HLA Class ǀ immunopeptides in melanoma and EGFR mutant lung adenocarcinoma (as deposited)
Paper describing it
- Proteogenomic Analysis Unveils the HLA Class I-Presented Immunopeptidome in Melanoma and EGFR-Mutant Lung Adenocarcinoma (2021, Molecular & Cellular Proteomics, peer-reviewed)